Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Diurnal

Diurnal
2004 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
DNL STOCK SYMBOL
$0.38 SHARE PRICE (As of Tuesday Closing)
Description

Diurnal Group PLC is a specialty pharmaceutical company developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism, and Hypothyroidism. The company has two products in late-stage clinical development targeting Adrenal diseases; Chronocort to be used for the treatment of Congenital Adrenal Hyperplasia and Adrenal Insufficiency in Adults and Infacort which is to be used for the same conditions in children. Its main country of operation is the United Kingdom.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Other Industries
Therapeutic Devices
Biotechnology
Stock Exchange
LON
Primary Office
  • Cardiff Medicentre
  • Heath Park
  • Cardiff CF14 4UJ
  • Wales, United Kingdom

+44 0871 000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Diurnal’s full profile, request a free trial.

Diurnal Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.26 - $0.74 $33.5M $0.39 -$0.25 134K 86.5M

Diurnal Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2019
30-Jun-2019
FY 2018
30-Jun-2018
FY 2017
30-Jun-2017
Enterprise Value 24,499 24,499 136,788 61,529
Revenue 1,351 1,351 98 0
EBITDA (18,503) (18,503) (22,556) (15,292)
Net Income (15,902) (15,902) (19,679) (11,952)
Total Assets 17,061 17,061 29,471 31,131
Total Debt 0 0 0 4,568
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Diurnal Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Diurnal‘s full profile, request access.

Request full access to PitchBook

Diurnal Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Diurnal‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Diurnal Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Diurnal‘s full profile, request access.

Request full access to PitchBook

Diurnal Executive Team (6)

Name Title Board
Seat
Contact
Info
Martin Whitaker Ph.D Chief Executive Officer & Board Member
Hiep Huatan Ph.D Chief Development Officer
Richard Ross Chief Scientific Officer & Board Member
Geoffrey Tucker Ph.D Consultant
David Eckland Director Clinical & Regulatory
You’re viewing 5 of 6 executives. Get the full list »

Diurnal Board Members (7)

Name Representing Role Since Contact
Info
Jonny Laughton Self Director 000 0000
Kevin Bryett Self Board Member 000 0000
Martin Whitaker Ph.D Diurnal Chief Executive Officer & Board Member 000 0000
Richard Ross Diurnal Chief Scientific Officer & Board Member 000 0000

3 Former Board Members

You’re viewing 4 of 7 board members. Get the full list »